October 12, 2012 — Biotronik announced the start of the prospective multicenter PARCADIA study. The study aims to identify risk factors that can help predict appropriate ICD interventions in patients with ischemic cardiomyopathy who have received an ICD for primary prevention according to the current ESC (European Society of Cardiology) guidelines.


October 12, 2012 — Boston Scientific announced it has enrolled the first patient in the REPRISE II clinical trial to evaluate the safety and performance of the Lotus valve system in up to 120 patients with severe aortic valve disease.

October 12, 2012 — Estech, a provider of minimally invasive cardiac ablation devices, last month announced the market release of its Cobra Fusion ablation system.

TyRx Inc. announced that it has received a license from Health Canada to market its AigisRx Antibacterial Envelope. The AigisRx Envelope is specifically designed to stabilize pacemakers and implantable cardioverter defibrillators (ICD) while also releasing antimicrobial agents to help provide protection from microbial colonization of the device during surgical implantation.

October 11, 2012 — Spectranetics Corp. announced the U.S. market launch of the Tapas catheter at the 2012 Vascular Interventional Advances (VIVA) conference in Las Vegas. Tapas is manufactured by ThermopeutiX Inc. and distributed by Spectranetics.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now